Peer-reviewed veterinary case report
Canine foot pad malignant melanoma cases and outcomes
By Jeon, Mark D et al.·Published in Veterinary and comparative oncology·2022·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Multi-institutional retrospective study of canine foot pad malignant melanomas: 20 cases.
- Species:
- dog
Plain-English summary
A dog with a foot pad melanoma, a type of skin cancer, was part of a study involving 20 dogs diagnosed with this rare condition. Some of the dogs received treatments like chemotherapy, radiation, or a special vaccine after surgery. Unfortunately, about 55% of the dogs developed further spread of the cancer, and the average survival time for those treated was around 240 days. This highlights that while foot pad melanomas can be aggressive, there are treatment options available that may help manage the disease.
People also search for: dog foot pad melanoma treatment · canine melanoma vaccine · dog skin cancer survival rate
Abstract
Melanomas arising from the foot pad are a rare clinical entity in dogs. The biologic behaviour of foot pad malignant melanoma is not well understood, and these tumours are infrequently described. The objective of this study was to evaluate the clinical characteristics of primary canine foot pad melanoma in a larger cohort of patients. Eligible cases were solicited from the American College of Veterinary Internal Medicine (ACVIM) Oncology listserv for retrospective review. Included dogs had a cytologic and/or histologic diagnosis of foot pad melanoma evaluated by a board-certified clinical or anatomic pathologist. Dogs with cutaneous, oral, digital, subungual or interdigital melanomas were excluded. A total of 20 cases were included. Eleven dogs received various adjuvant therapies including chemotherapy, radiation therapy, and/or the ONCEPT canine melanoma vaccine following surgery. At diagnosis, regional lymph node metastasis was observed in four dogs (20%). Seven dogs developed subsequent regional and/or distant metastasis for an overall metastatic rate of 55%. The progression-free interval (PFI) was 101 days (range, 20-960 days). The median survival time (MST) was 240 days (range, 25-479 days). For dogs receiving adjuvant therapy, the MST was 159 days (range, 25-387 days). Canine foot pad melanoma is a rare neoplasm that can exhibit an aggressive behaviour.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/35771690/